+Compare
BMRN
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
16.69B

BMRN BioMarin Pharmaceutical Forecast, Technical & Fundamental Analysis

a developer of innovative pharmaceuticals for serious diseases & medical conditions

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for BMRN with price predictions
07:00 PM EST Nov 29, 2023

BMRN in upward trend: price may jump up because it broke its lower Bollinger Band on November 06, 2023

BMRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 33 cases where BMRN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 07, 2023. You may want to consider a long position or call options on BMRN as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BMRN just turned positive on November 07, 2023. Looking at past instances where BMRN's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

BMRN moved above its 50-day moving average on November 15, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BMRN crossed bullishly above the 50-day moving average on November 21, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMRN advanced for three days, in of 298 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMRN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BMRN entered a downward trend on November 13, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BMRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.376) is normal, around the industry mean (20.645). P/E Ratio (113.636) is within average values for comparable stocks, (137.274). Projected Growth (PEG Ratio) (1.113) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (7.257) is also within normal values, averaging (329.009).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 0%. For the same Industry, the average monthly price growth was 25%, and the average quarterly price growth was 21%. AMPE experienced the highest price growth at 173%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 92%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was 94%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 59
SMR Rating: 94
Profit Risk Rating: 95
Seasonality Score: 25 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

BMRN is expected to report earnings to fall 47.37% to 24 cents per share on February 21

BioMarin Pharmaceutical BMRN Stock Earnings Reports
Q4'23
Est.
$0.24
Q3'23
Beat
by $0.23
Q2'23
Beat
by $0.31
Q1'23
Beat
by $0.39
Q4'22
Beat
by $0.06
The last earnings report on November 01 showed earnings per share of 46 cents, beating the estimate of 23 cents. With 84.81K shares outstanding, the current market capitalization sits at 16.69B.
A.I. Advisor
published General Information

General Information

a developer of innovative pharmaceuticals for serious diseases & medical conditions

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
770 Lindaro Street
Phone
+1 415 506-6700
Employees
3082
Web
http://www.bmrn.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DHC2.340.10
+4.24%
Diversified Healthcare Trust
KEP7.280.07
+0.97%
Korea Electric Power Corp
PSMT67.39-0.22
-0.33%
PriceSmart
PLG1.16-0.02
-1.69%
Platinum Group Metals Ltd
WHLR0.38-0.13
-25.47%
Wheeler Real Estate Investment Trust

BMRN and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMRN has been loosely correlated with ALNY. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if BMRN jumps, then ALNY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMRN
1D Price
Change %
BMRN100%
+1.49%
ALNY - BMRN
47%
Loosely correlated
+2.57%
MDGL - BMRN
46%
Loosely correlated
+3.01%
SRPT - BMRN
45%
Loosely correlated
+1.03%
AGIO - BMRN
42%
Loosely correlated
+0.05%
FOLD - BMRN
42%
Loosely correlated
+2.42%
More

Groups containing BMRN

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMRN
1D Price
Change %
BMRN100%
+1.49%
pharmaceuticals
(undefined stocks)
48%
Loosely correlated
-0.66%
drugs
(undefined stocks)
47%
Loosely correlated
-0.56%
biotechnology
(undefined stocks)
43%
Loosely correlated
-0.70%
innovating biotech
(undefined stocks)
33%
Poorly correlated
-0.37%